Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 10-17

  Saarto, T ^a   Blomqvist, C ^a   Virkkunen, P ^a   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CLODRONIC ACID; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 0035148170     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.10     Document Type: Article

References (26)

1. The clinical course of bone metastases from breast cancer
2. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
3. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
4. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
5. Characteristic of clodronate-induced apoptosis in osteoclasts and macrophages
6. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide independent mechanism
7. Apoptosis in phagocytotic cells of lymphoid tissue in rainbow trout (Oncorhynchus mykiss) following administration of clodronate liposomes
8. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumor activity
9. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
10. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton
11. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
12. Palliative pamidronate treatment in patients with bone metastases from breast cancer
13. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
14. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
15. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
16. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
17. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
18. Chemical castration induced by adjuvant CMF therapy causes a rapid bone loss which is reduced by clodronate: A randomized study in premenopausal breast cancer women
19. Clodronate improves bone mineral density in postmenopausal breast cancer women treated with adjuvant antiestrogens
20. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
21. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
22. Diphosphonates for osteolytic metastases
23. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer
24. Actions of bisphosphonates on bone metastasis in animal models of breast cancer
25. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice